S
Sabino De Placido
Researcher at University of Naples Federico II
Publications - 25
Citations - 1190
Sabino De Placido is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Breast cancer & Population. The author has an hindex of 14, co-authored 25 publications receiving 775 citations.
Papers
More filters
Journal ArticleDOI
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
Richard Gray,Rosie Bradley,Jeremy P Braybrooke,Z Liu,Richard Peto,Lucy Davies,David Dodwell,Paul McGale,Hongchao Pan,Carolyn W. Taylor,William E. Barlow,Judith M Bliss,Paolo Bruzzi,David Cameron,George Fountzilas,Sibylle Loibl,John R. Mackey,Miguel Martín,Lucia Del Mastro,Volker Möbus,Valentina Nekljudova,Sabino De Placido,Sandra M. Swain,Michael Untch,Kathleen I. Pritchard,Jonas Bergh,Larry Norton,Clare Boddington,Julie Ann Burrett,Mike Clarke,C Davies,Fran Duane,Vaughan Evans,Lucy Gettins,Jon Godwin,Robert Kerrin Hills,Sam James,Hui Liu,Elizabeth MacKinnon,Gurdeep S. Mannu,Theresa McHugh,Philip Morris,Simon Read,Yaochen Wang,Zhe Wang,Peter A. Fasching,Nadia Harbeck,Pascal Piedbois,Michael Gnant,Guenther G. Steger,Angelo Di Leo,Stella Dolci,Prue Francis,Denis Larsimont,Jean Marie Nogaret,Catherine Philippson,Martine Piccart,Sabine C. Linn,Petronella Peer,Vivianne C. G. Tjan-Heijnen,Sonja Vliek,Dennis J. Slamon,John D. Bartlett,Vivien H.C. Bramwell,Bingshu E. Chen,Stephen Chia,Karen A. Gelmon,Paul E. Goss,Mark Levine,Wendy R. Parulekar,Joseph L. Pater,Eileen Rakovitch,Lois E. Shepherd,Dongsheng Tu,Timothy J. Whelan,Donald A. Berry,Gloria Broadwater,Constance Cirrincione,Hyman B. Muss,Raymond B. Weiss,Yi Shan,Yong Fu Shao,Xiang Wang,Binghe Xu,Dong-Bing Zhao,Harry Bartelink,Nina Bijker,Jan Bogaerts,Fatima Cardoso,Tanja Cufer,J.P. Julien,Philip Poortmans,Emiel J. Th. Rutgers,Cornelis J.H. van de Velde,Eva Carrasco,Miguel Angel Segui,Jens Uwe Blohmer,Serban Costa,Bernd Gerber,Christian Jackisch,Gunter von Minckwitz,Mario Giuliano,Michele De Laurentiis,Christina Bamia,Georgia-Angeliki Koliou,Dimitris Mavroudis,Roger A'Hern,Paul Ellis,Lucy Kilburn,James P Morden,John Yarnold,Mohammad Sadoon,Augustinus H Tulusan,Stewart J. Anderson,Gordon Bass,J. Costantino,James J. Dignam,Bernard Fisher,Charles E. Geyer,Eleftherios P. Mamounas,Soon Paik,Carol Redmond,D. Lawrence Wickerham,M. Venturini,Claudia Bighin,Simona Pastorino,Paolo Pronzato,Mario Roberto Sertoli,Theodorus Foukakis,Kathy S. Albain,Rodrigo Arriagada,Elizabeth Bergsten Nordström,Francesco Boccardo,Etienne Brain,Lisa A. Carey,Alan S. Coates,Robert E. Coleman,C Correa,Jack Cuzick,Nancy E. Davidson,Mitch Dowsett,Marianne Ewertz,John F. Forbes,Richard D. Gelber,Aron Goldhirsch,Pamela J. Goodwin,Daniel F. Hayes,Christopher Hill,James N. Ingle,Reshma Jagsi,Wolfgang Janni,Hirofumi Mukai,Yasuo Ohashi,Lori J. Pierce,Vinod Raina,Peter M. Ravdin,Daniel Rea,Meredith M. Regan,John F.R. Robertson,Joseph A. Sparano,Andrew Tutt,Giuseppe Viale,Nicholas Wilcken,Norman Wolmark,Wiliam Wood,Milvia Zambetti +165 more
TL;DR: Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes.
Journal ArticleDOI
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
Francesco Schettini,Irene De Santo,Carmen G. Rea,Pietro De Placido,Luigi Formisano,Mario Giuliano,Grazia Arpino,Michelino De Laurentiis,Fabio Puglisi,Sabino De Placido,Lucia Del Mastro +10 more
TL;DR: Biological, preclinical and clinical data on the role of CDK4/6 inhibitors as single agent therapy for pretreated HR+ HER2– MBC are reviewed.
Journal ArticleDOI
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Mario Giuliano,Mario Giuliano,Francesco Schettini,Francesco Schettini,Carla Rognoni,Manuela Milani,Guy Jerusalem,Thomas Bachelot,Michelino De Laurentiis,Guglielmo Thomas,Pietro De Placido,Grazia Arpino,Sabino De Placido,Massimo Cristofanilli,Antonio Giordano,Fabio Puglisi,Barbara Pistilli,Aleix Prat,Lucia Del Mastro,Sergio Venturini,Sergio Venturini,Daniele Generali +21 more
TL;DR: The data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer.
Journal ArticleDOI
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
Ciro Santoro,Grazia Arpino,Roberta Esposito,Maria Lembo,Immacolata Paciolla,Cinzia Cardalesi,Giovanni de Simone,Bruno Trimarco,Sabino De Placido,Maurizio Galderisi +9 more
TL;DR: 2D GLS is superior to standard echo and presents a good feasibility of 3D EF and 3D strain in diagnosing subclinical ANT cardiotoxicity in breast cancer patients, demonstrating potential superiority but also suboptimal feasibility.
Journal ArticleDOI
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Giuseppe Buono,Lorenzo Gerratana,Lorenzo Gerratana,Michela Bulfoni,Nicoletta Provinciali,Debora Basile,Mario Giuliano,C. Corvaja,Grazia Arpino,Lucia Del Mastro,Sabino De Placido,Michele De Laurentiis,Massimo Cristofanilli,Fabio Puglisi +13 more
TL;DR: Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.